Anti-Aging Drug Combination Damages Nerve Insulation in Mice Study
Similar Articles
Topical Drug Reduces Aging Signs and Speeds Wound Healing in Mice
Researchers Restore Memory in Dementia Models by Fixing Mitochondrial Activity
Engineered Nanoparticles Show Promise in Restoring Brain Waste Removal in Alzheimer's Mouse Model
New Drugs Target 'Zombie' Cells to Combat Cancer and Aging
Two Drug Molecules Identified That Trigger Myelin Regrowth in MS Models
A drug combination being explored for anti-aging and diseases like Alzheimer's was found to damage the protective myelin coating around nerves in mice. The study found the treatment caused myelin loss, particularly in younger animals, and altered the brain cells responsible for its production. The findings highlight a potential risk for a promising class of therapies.
Facts First
- The drug combination dasatinib+quercetin (D+Q) damaged myelin in mice, with younger animals experiencing greater loss.
- Myelin is the protective nerve coating whose loss is associated with numbness, pain, and cognitive problems.
- The treatment caused oligodendrocytes, the cells that make myelin, to regress into a more juvenile form rather than die.
- D+Q is currently researched for anti-aging and conditions including type II diabetes and Alzheimer's disease.
- The altered mouse cells resembled a cell population previously identified in people with multiple sclerosis.
What Happened
Researchers at the University of Connecticut (UConn) published a study showing the anti-aging drug combination dasatinib+quercetin (D+Q) damaged myelin in mice. The study tested D+Q on young and old mice, as well as on oligodendrocytes grown in lab dishes. In treated mice, myelin layers were dramatically reduced, with younger mice experiencing greater damage. The corpus callosum, a structure connecting the brain's two halves, also deteriorated. The oligodendrocytes did not die but regressed into a more juvenile form with abnormal metabolism.
Why this Matters to You
Drugs like D+Q are being actively researched to combat age-related diseases, which could one day affect treatments available to you or your family. This research suggests a potential side effect—damage to nerve insulation—that may need to be carefully managed if these therapies move forward. For now, it is a cautionary finding from animal studies, but it underscores the complexity of developing treatments that target fundamental aging processes.
What's Next
The research team has identified a specific cellular risk. This finding may lead to further studies to understand the mechanism of myelin damage and to see if the effect is reversible. Future research will likely need to determine if this risk applies to humans and whether it can be mitigated, which could be a critical step before D+Q or similar senolytic therapies are widely used for age-related conditions.